Schrödinger, Inc. (NASDAQ:SDGR) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET

Company Participants

Jaren Madden – Senior Vice President of Investor Relations and Corporate Affairs

Ramy Farid – Chief Executive Officer

Jenny Herman – Senior Vice President of Finance and Corporate Controller

Karen Akinsanya – President of R&D, Therapeutics

Conference Call Participants

Vikram Purohit – Morgan Stanley

David Lebowitz – Citi

Andrew Tsai – Jefferies

Gaurav Goparaju – Berenberg Capital

Operator

Welcome to Schrödinger’s Conference Call to review First Quarter 2022 Financial Results. My name is Charlie, and I’ll be your operator for today’s call. At this time, all participants are in a listen-only mode. After the speaker’s presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that this call is being recorded at the company’s request.

Now I would like to introduce your host for today’s conference, Ms. Jaren Madden, Senior Vice President of Investor Relations and Corporate Affairs. Please go ahead.

Jaren Madden

Thank you and good afternoon everyone. Welcome to today’s call during which we will provide an update on the company and review our first quarter 2022 financial results. Earlier today, we issued a press release summarizing our financial results and progress across the company, which is available on our website at www.schrodinger.com. Here with me on our call today are Ramy Farid, Chief Executive Officer; Jenny Herman, Senior Vice President of Finance and Corporate Controller; and Karen Akinsanya, President of R&D, Therapeutics.

Following our prepared remarks, we’ll open the call for Q&A. I’d like to remind you that during today’s call, management will make statements related to our business that are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, without limitations, statements related to our future financial performance, including our outlook for the full year 2022 and for the quarter ending June 30, 2022; our strategic plans to accelerate the growth of our software business and advance our collaborative and wholly-owned drug discovery programs; the timing of potential IND submissions and initiation of clinical trials for our wholly-owned drug discovery programs, risks related to the COVID-19 pandemic; our expectations related to the use of our cash, cash equivalents, and marketable securities; as well as our future operating expenses.

These forward-looking statements reflect our views about our plans, intentions, expectations, strategies, and prospects, which are based on the information available to us and on assumptions we have made. Actual results may differ materially from those described in the forward-looking statements and are subject to a variety of assumptions, uncertainties, risks, and important factors that are beyond our control, including the demand for our software solutions, our ability to develop our computational platform, our reliance upon our drug discovery collaborators and other risks detailed under the caption Risk Factors and elsewhere in our most recent Securities and Exchange Commission filings and reports. Except as required by law, we undertake no duty or obligation to provide any update on our forward-looking statements discussed on this call as a result of new information, future events, changes in expectations, or otherwise. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to today.